Navigation Links
Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
Date:8/14/2008

Turnover Increased by 45.7% Profit Attributable to Shareholders Increased Significantly by 161.7%

HONG KONG, Aug. 14 /Xinhua-PRNewswire/ -- Fufeng Group Limited ("Fufeng" or "the Group"; HKEx: 546), a leading vertically integrated manufacturer of corn-based biochemical products in China, today announces its interim results for the six months ended 30 June 2008.

During the period under review, driven by the increased sales volume and selling price of major products, the Group's turnover increased to RMB1,630.4 million, representing an increase of 45.7%. The Group's gross profit increased by 108.3% to RMB237.7 million, profit attributable to shareholders significantly increased by 161.7% to RMB85.9 million. The earnings per share for the 1H of 2008 amounted to RMB 5.17 cents.

Commenting on the results, Mr. Li Xuechun, Chairman of Fufeng said, "After the market downturn in 2007, the Group's results in the 1H of 2008 have shown a strong sign of recovery. During the period under review, we increased sales volume and enlarged market share in MSG market. As for xanthan gum, the Group successfully captured additional market share by capacity expansion and competitive selling price."

The Group's two major business segments showed a strong sign of recovery. In the 1H of 2008, the ASP of the Group's major products in the MSG segment has rebounded completely. The sales volume of glutamic acid also increased by 15.6% in the 1H of 2008 from that of 2007. With the Group's strategy of moving from glutamic acid to MSG, the sales volume of MSG continued to increase by approximately 11.5% in the 1H of 2008.

During the period, the sales volume of xanthan gum increased by 247.9% to 7,831 tonnes while the sales amount increased by 196% to RMB168.7 million. The gross profit of xanthan gum also increased by 183% to RMB57.2 million. The ASP of xanthan gum decreased by 14.8% to RMB21,547 per tonne in the 1H of 2008. However, th
'/>"/>

SOURCE Fufeng Group Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Fufeng Announces 2007 Annual Results
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The FBI recently approved the Promega Power...ating in or generating DNA records for the Nationa...ison, WI USA (PRWEB) -- The FBI recently approved ...by laboratories participating in, or generating DN...). NDIS currently contains more than seven million...
(Date:11/24/2009)...v.24,2009/PRNewswire-FirstCall/--ArenaPharmaceutic...anyisscheduledtopresentatthePiperJaffray21stAnnual...ternTime(8:30a.m.PacificTime)attheNewYorkPalaceHot...fExecutiveOfficer,isscheduledtoprovideanoverviewof...veryprograms. ,, Aliveaudiowebcastofthepresenta...
(Date:11/24/2009)... Chemical Abstracts Service (CAS), the globa...na,s patent office is now the world,s leading prod.... China trailed Japan,s patent office, the World I...United States Patent and Trademark Office (USPTO) ...05, WIPO in 2006, and exceeded Japan for the first...
(Date:11/23/2009)... promises ultra-fast communication, computation an...ion. But trying to use quantum states as carriers ...Now two physicists have shown, mathematically, how...munication, while keeping the information intact. ...ysical Review Letters and highlighted with a View...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
....C., Feb. 25 Attagene Inc., a,biotechnology compa...duction analysis, announced today that one of the ...hip technology, the FACTORIAL(TM). In,advance onli...gei Romanov,with colleagues describes a novel and ...porting on the activity of a large panel of transc...
...b. 25 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA... Phase 3 clinical trial with AZ-004 (Staccato(R) l...e being developed for the treatment of,acute agita...order. Alexza,believes the novel, non-invasive nat...lting from inhaled loxapine administration via the...
...st to Assess Genetic Risk of Thrombosis Improves, ...with Batch Processing, SUNNYVALE, Calif., and LEX...epheid (Nasdaq: CPHD ) and Instrumentation Labora... today announced the release of the Xpert (TM),Hem...roduct under the,European Directive on In Vitro Di...
Other Biology Technology:Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 2Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 2Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 3Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 4Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 5
(Date:11/24/2009)...ion of a remarkable class of ring-shaped protein m...awrence Berkeley National Laboratory (Berkeley Lab... beamline at the Advanced Light Source (ALS). Thes...sion and replication, and are vital to the surviva...gents, such as the human papillomavirus, which has...
(Date:11/24/2009)...YORK (November 24, 2009) -- The Wildlife Conservat...ng that the last remaining population of Siberian ...e rising tide of poaching and habitat loss. , ...sian officials of what needs to be done to protect... , The report was released by the S...
(Date:11/24/2009)...sh food is a matter of debate. A high-profile stud...0 percent of their carbon from trees and leaves, e...ial and aquatic ecosystems. , But new research f... likely to be true. Algae provide a much richer di...esearch published this week in the Proceedings of...
Breaking Biology News(10 mins):Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Report shows dramatic decline in Siberian tigers 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 1European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 2Pioneer of Digital Place Based Media Joins World 26apos 3Bs Leading Blood Pressure and Health Kiosk Manufacturer 51199 1Pioneer of Digital Place Based Media Joins World 26apos 3Bs Leading Blood Pressure and Health Kiosk Manufacturer 51199 2Life Spine 28R 29 Announces FDA Clearance of FS3 28TM 29 Minimally Invasive Spinal System 51196 1
...l repairs or replicates its DNA, the resulting sin...mplex. In eukaryotes or organisms whose cells have...mplex called replication protein A (RPA). Research...ave now unearthed a novel RPA-like complex that sp...NA "tail" end of yeast chromosomes. , Their findin...
...he University of California, Santa Cruz, have dete...nzyme, or "ribozyme," that carries out a fundament...eir results provide insight into what may have bee...lions of years ago on the evolutionary path toward...wn today, the synthesis of DNA and RNA molecules i...
...ack baby" hysteria of the 1980s was greatly exagge...le but disabling cognitive impairments -- attentio...oblems. , A recent study by investigators at the ...velopment may help explain the long-term behaviora...al exposure to cocaine. In a recent issue of the J...
Other Biology News:DNA ends: Common tool, different job 2RNA enzyme structure offers a glimpse into the origins of life 2Prenatal cocaine's lasting cellular effects 2Prenatal cocaine's lasting cellular effects 3
Chicken Anti-Human Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
Anti-p38 MAP Kinase gamma Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-Arg Vasopressin Polyclonal Antibody, Unconjugated from ImmunoStar, Inc.
Goat Anti-Human JIK Polyclonal Antibody, Unconjugated from Abcam
Biology Products: